CRISPR Therapeutics AG

CRSP

CH0334081137

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 09:36:33 2024-07-05 EDT			5-day change	1st Jan Change
52.97 ^USD	-1.73%		-2.67%	-13.90%

06-11	Transcript : CRISPR Therapeutics AG Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 09:20 AM
05-23	CRISPR Therapeutics Names Naimish Patel as Chief Medical Officer; Promotes Julianne Bruno to Chief Operating Officer	MT

CRISPR Therapeutics AG Appoints Lawrence O. Klein as Chief Operating Officer

January 29, 2020 at 04:18 pm

Effective as of January 26, 2020, Lawrence O. Klein, Ph.D., the Chief Business Officer of CRISPR Therapeutics AG was also appointed to serve as the Company’s Chief Operating Officer.

Latest news about CRISPR Therapeutics AG

Transcript : CRISPR Therapeutics AG Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 09:20 AM	06-11
CRISPR Therapeutics Names Naimish Patel as Chief Medical Officer; Promotes Julianne Bruno to Chief Operating Officer	05-23	MT
CRISPR Therapeutics Announces Executive Changes	05-23	CI
Transcript : CRISPR Therapeutics AG Presents at Bank of America Health Care Conference 2024, May-15-2024 09:20 AM	05-15
Oppenheimer Adjusts CRISPR Therapeutics Price Target to $95 From $102, Maintains Outperform Rating	05-10	MT
Barclays Adjusts Price Target on CRISPR Therapeutics to $67 From $80, Maintains Equal-Weight Rating	05-09	MT
Needham Adjusts Price Target on CRISPR Therapeutics to $88 From $90, Keeps Buy Rating	05-09	MT
Baird Adjusts Price Target on CRISPR Therapeutics to $52 From $46, Keeps Neutral Rating	05-09	MT
CRISPR Therapeutics AG Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Reports Q1 Revenue $504,000	05-08	MT
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach	05-08	CI
Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating	04-18	MT
Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing	04-17	MT
Mizuho Adjusts Price Target on CRISPR Therapeutics to $99 From $82, Maintains Buy Rating	03-06	MT
Morgan Stanley Adjusts Price Target on CRISPR Therapeutics to $48 From $46, Maintains Underweight Rating	02-26	MT
Wells Fargo Raises Price Target on CRISPR Therapeutics to $70 From $55, Maintains Equal-Weight Rating	02-22	MT
Barclays Raises Price Target on CRISPR Therapeutics to $80 From $61, Maintains Equal-Weight Rating	02-22	MT
Chardan Ups Price Target on CRISPR Therapeutics to $112 From $110, Keeps Buy Rating	02-22	MT
RBC Raises Price Target on CRISPR Therapeutics to $66 From $57 on Strengthened Balance Sheet, Casgevy Approval; Sector Perform, Speculative Risk Kept	02-22	MT
Transcript : CRISPR Therapeutics AG Presents at Citi 2024 Virtual Oncology Leadership Summit, Feb-21-2024 10:00 AM	02-21
Needham Adjusts CRISPR Therapeutics' Price Target to $90 From $88, Keeps Buy Rating	02-21	MT
CRISPR Therapeutics Swings to Q4 Profit, Revenue Increases	02-21	MT
CRISPR Therapeutics AG Reports Earnings Results for the Full Year Ended December 31, 2023	02-21	CI
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Reports Q4 Revenue $201.2M	02-21	MT
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Posts Q4 EPS $1.10	02-21	MT

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

Sector

Biotechnology & Medical Research

Calendar

2024-07-28 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for CRISPR Therapeutics AG

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

53.9 USD

Average target price

86.57 USD

Spread / Average Target

+60.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CRISPR THERAPEUTICS AG	-13.90%	4.58B
MODERNA, INC.	+16.59%	44.44B
LONZA GROUP AG	+43.00%	40.03B
IQVIA HOLDINGS INC.	-10.62%	37.68B
ALNYLAM PHARMACEUTICALS, INC.	+29.92%	31.46B
CELLTRION, INC.	-9.23%	27.29B
ICON PUBLIC LIMITED COMPANY	+12.34%	26.29B
UNITED THERAPEUTICS CORPORATION	+41.53%	13.8B
MEDPACE HOLDINGS, INC.	+31.49%	12.46B
BIO-TECHNE CORPORATION	-7.40%	11.26B

Other Biotechnology & Medical Research